Hepatocellular carcinoma (HCC) is one of the deadliest forms of human liver cancer and does not respond well to conventional therapies. Novel effective treatments are urgently in need. G‐protein‐coupled kinase 2 (GRK2) is unique serine/threonine kinase that involves in many signaling pathways and regulates various essential cellular processes. Altered levels of GRK2 have been linked with several human diseases including cancer. In this study, we investigated a novel approach for HCC treatment by inducing overexpression of GRK2 in human HCC cells. We found that overexpression of GRK2 through recombinant adenovirus transduction inhibits the growth of human HCC cells. BrdU incorporation assay showed that the growth inhibition caused by elevated GRK2 level was due to reduced cell proliferation but not apoptosis. To examine the anti‐proliferative function of increased GRK2 level, we performed cell cycle analysis using propidium iodide staining. We found that the proliferation suppression was associated with G2/M phase cell cycle arrest by the wild‐type GRK2 but not its kinase‐dead K220R mutant. Furthermore, increased levels of wild‐type GRK2 induced upregulation of phosphor‐Ser¹⁵ p53 and cyclin B1 in a dose‐dependent manner. Our data indicate that the anti‐proliferative function of elevated GRK2 is associated with delayed cell cycle progression and is GRK2 kinase activity‐dependent. Enforced expression of GRK2 in human HCC by molecular delivery may offer a potential therapeutic approach for the treatment of human liver cancer. J. Cell. Physiol. 227: 2371–2377, 2012. © 2011 Wiley Periodicals, Inc.